Abstract
Original language | English |
---|---|
Article number | e0230815 |
Pages (from-to) | e0230815 |
Number of pages | 17 |
Journal | PloS ONE |
Volume | 15 |
Issue number | 5 |
DOIs | |
Publication status | Published - 7 May 2020 |
Keywords
- GENOME-WIDE ASSOCIATION
- INSULIN-RESISTANCE
- GENETIC-VARIANTS
- CIGARETTE-SMOKING
- COMMON VARIANTS
- BODY-FAT
- LOCI
- NICOTINE
- INSIGHTS
- DISEASE
Access to Document
- 10.1371/journal.pone.0230815Licence: CC0
- Wu_et_al_pone_SmokingByGenotype_VoR
This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. https://creativecommons.org/publicdomain/zero/1.0/
Final published version, 807 KBLicence: CC0
Fingerprint Dive into the research topics of 'Smoking-by-genotype interaction in type 2 diabetes risk and fasting glucose'. Together they form a unique fingerprint.
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Smoking-by-genotype interaction in type 2 diabetes risk and fasting glucose. / Wu, Peitao; Rybin, Denis; Bielak, Lawrence F.; Feitosa, Mary F.; Franceschini, Nora; Li, Yize; Lu, Yingchang; Marten, Jonathan; Musani, Solomon K.; Noordam, Raymond; Raghavan, Sridharan; Rose, Lynda M.; Schwander, Karen; Smith, Albert V.; Tajuddin, Salman M.; Vojinovic, Dina; Amin, Najaf; Arnett, Donna K.; Bottinger, Erwin P.; Demirkan, Ayse; Florez, Jose C.; Ghanbari, Mohsen; Harris, Tamara B.; Launer, Lenore J.; Liu, Jingmin; Liu, Jun; Mook-Kanamori, Dennis O.; Murray, Alison D.; Nalls, Mike A.; Peyser, Patricia A.; Uitterlinden, André G.; Voortman, Trudy; Bouchard, Claude; Chasman, Daniel; Correa, Adolfo; de Mutsert, Renée; Evans, Michele K.; Gudnason, Vilmundur; Hayward, Caroline; Kao, Linda; Kardia, Sharon L. R.; Kooperberg, Charles; Loos, Ruth J. F.; Province, Michael M.; Rankinen, Tuomo; Redline, Susan; Ridker, Paul M.; Rotter, Jerome I.; Siscovick, David; Smith, Blair H.; van Duijn, Cornelia; Zonderman, Alan B.; Rao, D. C.; Wilson, James G.; Dupuis, Josée; Meigs, James B.; Liu, Ching-Ti; Vassy, Jason L.
In: PloS ONE, Vol. 15, No. 5, e0230815, 07.05.2020, p. e0230815.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Smoking-by-genotype interaction in type 2 diabetes risk and fasting glucose
AU - Wu, Peitao
AU - Rybin, Denis
AU - Bielak, Lawrence F.
AU - Feitosa, Mary F.
AU - Franceschini, Nora
AU - Li, Yize
AU - Lu, Yingchang
AU - Marten, Jonathan
AU - Musani, Solomon K.
AU - Noordam, Raymond
AU - Raghavan, Sridharan
AU - Rose, Lynda M.
AU - Schwander, Karen
AU - Smith, Albert V.
AU - Tajuddin, Salman M.
AU - Vojinovic, Dina
AU - Amin, Najaf
AU - Arnett, Donna K.
AU - Bottinger, Erwin P.
AU - Demirkan, Ayse
AU - Florez, Jose C.
AU - Ghanbari, Mohsen
AU - Harris, Tamara B.
AU - Launer, Lenore J.
AU - Liu, Jingmin
AU - Liu, Jun
AU - Mook-Kanamori, Dennis O.
AU - Murray, Alison D.
AU - Nalls, Mike A.
AU - Peyser, Patricia A.
AU - Uitterlinden, André G.
AU - Voortman, Trudy
AU - Bouchard, Claude
AU - Chasman, Daniel
AU - Correa, Adolfo
AU - de Mutsert, Renée
AU - Evans, Michele K.
AU - Gudnason, Vilmundur
AU - Hayward, Caroline
AU - Kao, Linda
AU - Kardia, Sharon L. R.
AU - Kooperberg, Charles
AU - Loos, Ruth J. F.
AU - Province, Michael M.
AU - Rankinen, Tuomo
AU - Redline, Susan
AU - Ridker, Paul M.
AU - Rotter, Jerome I.
AU - Siscovick, David
AU - Smith, Blair H.
AU - van Duijn, Cornelia
AU - Zonderman, Alan B.
AU - Rao, D. C.
AU - Wilson, James G.
AU - Dupuis, Josée
AU - Meigs, James B.
AU - Liu, Ching-Ti
AU - Vassy, Jason L.
N1 - Data Availability: Our study data are now available at the following URL on the AMP T2D Knowledge Portal: http://www.kp4cd.org/dataset_downloads/t2d. Funding: WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. The grant funding of WHI are R21 HL123677, R56 DK104806 and R01 MD012765 to NF. The FamHS was funded by R01HL118305 and R01HL117078 NHLBI grants, and 5R01DK07568102 and 5R01DK089256 NIDDK grant." and "The Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study was supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health (project # Z01-AG000513 and human subjects protocol number 09-AGN248). Support for GENOA was provided by the National Heart, Lung and Blood Institute (HL119443, HL087660, HL054464, HL054457, and HL054481) of the National Institutes of Health. Ruth loos is supported by the NIH (R01DK110113, U01HG007417, R01DK101855, R01DK107786). The Rotterdam Study GWAS datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), and the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 050-060-810. The ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006- 01947) and also received funding from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by the European Commission under the programme "Quality of Life and Management of the Living Resources" of 5th Framework Programme (no. QLG2-CT-2002- 01254). The ERF study was further supported by ENGAGE consortium and CMSB. Highthroughput analysis of the ERF data was supported by joint grant from Netherlands Organisation for Scientific Research and the Russian Foundation for Basic Research (NWORFBR 047.017.043).ERF was further supported by the ZonMw grant (project 91111025), and this work was partially supported by the National Heart, Lung and Blood Institute’s Framingham Heart Study (Contract No. N01-HC25195) and its contract with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6- 4278). This study is also supported by National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK078616 to Drs. Meigs, Dupuis and Florez, NIDDK K24 DK080140 to Dr. Meigs, and a Doris Duke Charitable Foundation Clinical Scientist Development Award to Dr. Florez. The HERITAGE Family Study was supported by National Heart, Lung, and Blood Institute grant HL-45670. The Women's Genome Health Study is supported by the National Heart, Lung, and Blood Instutute (HL043851 and HL080467) and the National Cancer Institute (CA047988 and UM1CA182913). Additional support for endpoint collection was provided by the National Heart, Lung, and Blood Institute under ARRA funding (HL099355). HyperGEN (Hypertension Genetic Epidemiology Network): The hypertension network is funded by cooperative agreements (U10) with NHLBI: HL54471, HL54472, HL54473, HL54495, HL54496, HL54497, HL54509, HL54515, and 2 R01 HL55673- 12. The AGES study has been funded by NIH contracts N01-AG-1-2100 and 271201200022C. Caroline Hayward is supported by an MRC University Unit Programme Grant MC_UU_00007/10 (QTL in Health and Disease)”and “Generation Scotland received core funding from the Chief Scientist Office of the Scottish Government Health Directorate CZD/16/6, the Scottish Funding Council HR03006 and the Wellcome Trust through a Strategic Award (reference 104036/Z/14/Z) for Stratifying Resilience and Depression Longitudinally (STRADL). Genotyping was funded by the UK's Medical Research Council. Jose C. Florez, NIDDK K24 DK110550 The MESA project is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420, UL1-TR-001881, and DK063491. Additionally, one or more authors are affiliated with the following commercial entities: Interleukin Genetics, GlaxoSmithKline, Daiichi-Sankyo, AstraZeneca, Data Tecnica International LLC, Illumina Inc., University of California Healthcare, Janssen Pharmaceuticals, Goldfinch Bio, and Novo Nordisk. Please see the Competing Interests Statement for additional details. The funders provided support in the form of salaries for authors but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.
PY - 2020/5/7
Y1 - 2020/5/7
N2 - Smoking is a potentially causal behavioral risk factor for type 2 diabetes (T2D), but not all smokers develop T2D. It is unknown whether genetic factors partially explain this variation. We performed genome-environment-wide interaction studies to identify loci exhibiting potential interaction with baseline smoking status (ever vs. never) on incident T2D and fasting glucose (FG). Analyses were performed in participants of European (EA) and African ancestry (AA) separately. Discovery analyses were conducted using genotype data from the 50,000-single-nucleotide polymorphism (SNP) ITMAT-Broad-CARe (IBC) array in 5 cohorts from from the Candidate Gene Association Resource Consortium (n = 23,189). Replication was performed in up to 16 studies from the Cohorts for Heart Aging Research in Genomic Epidemiology Consortium (n = 74,584). In meta-analysis of discovery and replication estimates, 5 SNPs met at least one criterion for potential interaction with smoking on incident T2D at p<1x10-7 (adjusted for multiple hypothesis-testing with the IBC array). Two SNPs had significant joint effects in the overall model and significant main effects only in one smoking stratum: rs140637 (FBN1) in AA individuals had a significant main effect only among smokers, and rs1444261 (closest gene C2orf63) in EA individuals had a significant main effect only among nonsmokers. Three additional SNPs were identified as having potential interaction by exhibiting a significant main effects only in smokers: rs1801232 (CUBN) in AA individuals, rs12243326 (TCF7L2) in EA individuals, and rs4132670 (TCF7L2) in EA individuals. No SNP met significance for potential interaction with smoking on baseline FG. The identification of these loci provides evidence for genetic interactions with smoking exposure that may explain some of the heterogeneity in the association between smoking and T2D.
AB - Smoking is a potentially causal behavioral risk factor for type 2 diabetes (T2D), but not all smokers develop T2D. It is unknown whether genetic factors partially explain this variation. We performed genome-environment-wide interaction studies to identify loci exhibiting potential interaction with baseline smoking status (ever vs. never) on incident T2D and fasting glucose (FG). Analyses were performed in participants of European (EA) and African ancestry (AA) separately. Discovery analyses were conducted using genotype data from the 50,000-single-nucleotide polymorphism (SNP) ITMAT-Broad-CARe (IBC) array in 5 cohorts from from the Candidate Gene Association Resource Consortium (n = 23,189). Replication was performed in up to 16 studies from the Cohorts for Heart Aging Research in Genomic Epidemiology Consortium (n = 74,584). In meta-analysis of discovery and replication estimates, 5 SNPs met at least one criterion for potential interaction with smoking on incident T2D at p<1x10-7 (adjusted for multiple hypothesis-testing with the IBC array). Two SNPs had significant joint effects in the overall model and significant main effects only in one smoking stratum: rs140637 (FBN1) in AA individuals had a significant main effect only among smokers, and rs1444261 (closest gene C2orf63) in EA individuals had a significant main effect only among nonsmokers. Three additional SNPs were identified as having potential interaction by exhibiting a significant main effects only in smokers: rs1801232 (CUBN) in AA individuals, rs12243326 (TCF7L2) in EA individuals, and rs4132670 (TCF7L2) in EA individuals. No SNP met significance for potential interaction with smoking on baseline FG. The identification of these loci provides evidence for genetic interactions with smoking exposure that may explain some of the heterogeneity in the association between smoking and T2D.
KW - GENOME-WIDE ASSOCIATION
KW - INSULIN-RESISTANCE
KW - GENETIC-VARIANTS
KW - CIGARETTE-SMOKING
KW - COMMON VARIANTS
KW - BODY-FAT
KW - LOCI
KW - NICOTINE
KW - INSIGHTS
KW - DISEASE
UR - http://www.scopus.com/inward/record.url?scp=85084398003&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0230815
DO - 10.1371/journal.pone.0230815
M3 - Article
C2 - 32379818
VL - 15
SP - e0230815
JO - PloS ONE
JF - PloS ONE
SN - 1932-6203
IS - 5
M1 - e0230815
ER -